Circassia
-
Oxford-based Circassia reports revenue growth of 27%
The medical device company focused on point of care asthma diagnosis and management released a trading update for the six months ended 30 June 2021.
-
Circassia Pharmaceuticals to transfer respiratory medicine rights AstraZeneca
Circassia Pharmaceuticals has announced it intends to terminate its U.S. commercial rights to Tudorza® and Duaklir® and transfer the assets to AstraZeneca.
-
CIP Merchant Capital announces investment in Oxford-based Circassia
CIP Merchant Capital has announced its investment in Oxford-based Circassia, acquiring 12.8m ordinary shares, representing 3.4% of issued share capital, for £2.8m.
-
Circassia announces business update for 31 December 2019
Oxford-based Circassia Pharmaceuticals has announced a business update including a trading update for the year ended 31 December 2019.